Forbion taps Dyne vet Brumm to guide growing U.S. presence
Plus: Edward Dulac to become CFO at Intellia, and updates from Altimmune, Bayer, Compass, Sensorion and Neurona
In a bid to grow its U.S. footprint, Forbion hired Josh Brumm as general partner and unveiled plans for a new office in the U.S. in Boston. Brumm, who will be located at the European VC’s new Boston address, was most recently president and CEO of muscle disease company Dyne Therapeutics Inc. (NASDAQ:DYN), a Forbion portfolio company. Forbion said Brumm will hunt for new opportunities in North America and Europe and support existing portfolio companies, including those “working towards U.S. expansion.”
Edward Dulac will become EVP, CFO at Intellia Therapeutics Inc. (NASDAQ:NTLA) on July 22, succeeding Glenn Goddard, who is stepping down June 30. Dulac was CFO at Fate Therapeutics Inc. (NASDAQ:FATE), before which he held several roles at Celgene Corp. ...